Defender Capital LLC. Purchases 5,866 Shares of Danaher Co. (NYSE:DHR)

Defender Capital LLC. boosted its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 137,951 shares of the conglomerate's stock after acquiring an additional 5,866 shares during the quarter. Danaher accounts for 11.6% of Defender Capital LLC.'s portfolio, making the stock its 3rd largest position. Defender Capital LLC.'s holdings in Danaher were worth $31,667,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently bought and sold shares of DHR. Fort Pitt Capital Group LLC grew its holdings in shares of Danaher by 3.2% during the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate's stock worth $66,194,000 after purchasing an additional 7,421 shares during the last quarter. Good Life Advisors LLC bought a new stake in shares of Danaher during the third quarter worth $217,000. ORG Partners LLC grew its holdings in shares of Danaher by 1,212.8% during the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate's stock worth $636,000 after purchasing an additional 2,559 shares during the last quarter. Harvest Portfolios Group Inc. grew its holdings in shares of Danaher by 1.2% during the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate's stock worth $56,233,000 after purchasing an additional 2,465 shares during the last quarter. Finally, Stifel Financial Corp grew its holdings in shares of Danaher by 1.3% during the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate's stock worth $235,583,000 after purchasing an additional 11,216 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Down 0.5 %

Shares of NYSE:DHR traded down $1.01 during trading on Thursday, hitting $222.72. 4,269,414 shares of the company's stock traded hands, compared to its average volume of 3,488,701. The company has a market cap of $160.87 billion, a price-to-earnings ratio of 42.50, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a 50-day moving average price of $235.89 and a 200-day moving average price of $253.45. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 52 week low of $221.34 and a 52 week high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same period in the previous year, the business posted $2.09 EPS. As a group, research analysts forecast that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.48%. The ex-dividend date of this dividend is Friday, December 27th. Danaher's dividend payout ratio (DPR) is 20.61%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on DHR. Guggenheim began coverage on Danaher in a report on Thursday, December 19th. They issued a "buy" rating and a $275.00 price target on the stock. Jefferies Financial Group decreased their price target on Danaher from $285.00 to $260.00 and set a "buy" rating on the stock in a report on Wednesday. Citigroup decreased their price target on Danaher from $305.00 to $285.00 and set a "buy" rating on the stock in a report on Monday, January 6th. Robert W. Baird decreased their price target on Danaher from $277.00 to $268.00 and set an "overweight" rating on the stock in a report on Tuesday. Finally, UBS Group decreased their price target on Danaher from $309.00 to $305.00 and set a "buy" rating on the stock in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, Danaher has a consensus rating of "Moderate Buy" and a consensus target price of $278.95.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.